Results 191 to 200 of about 99,201 (311)

The silent pharmacist: Harnessing the gut microbiome to improve therapy in hematologic malignancies. [PDF]

Transl Oncol
El-Sehrawy AAMA, Soleimani Samarkhazan H.   +1 more
europepmc   +1 more source

BCMA‐Engineered Dendritic Cell‐Derived Exosomes as Bi‐Functional Therapeutics Orchestrating Cytokine Sequestration and Immune Activation for Multiple Myeloma

Advanced Science, EarlyView.
A dual‐function cell‐free therapeutic based on DC2.4 cell‐derived exosomes engineered to display BCMA. (Left) Soluble Ligand Sequestration (Decoy Function): DB Exo act as molecular decoys that predominantly sequester soluble APRIL with partial BAFF attenuation, effectively disrupting the NF‐κB survival signaling axis and suppressing myeloma cell ...
Yuqing Zeng, Chao He, Zhibin He, Hongbo Chen, Fang Cheng, Yongjiang Zheng   +5 more
wiley   +1 more source

Leveraging Dietary Interventions to Benefit Patients with Hematologic Malignancies and Clonal Hematopoiesis. [PDF]

Nutrients
Brzechffa C, Fleischman AG.
europepmc   +1 more source

p53 in hematologic malignancies [PDF]

Blood, 1994
J, Imamura, I, Miyoshi, H P, Koeffler
openaire   +3 more sources

Ciclopirox Olamine Inhibits the NLRP3 Inflammasome to Alleviate Inflammatory Diseases

Advanced Science, EarlyView.
There is no drug targeting the NLRP3 inflammasome that has been approved for use in clinical settings. Ciclopirox olamine (CPX), an antifungal agent approved by the US Food and Drug Administration (FDA), is identified as a specific and potent NLRP3 inflammasome inhibitor. CPX targets the NACHT domain of NLRP3 at Y381 to impair NLRP3 oligomerization and
Xinyu Xia, Hui You, Ke Zhang, Hui Jiang, Hongping Liu, Lianghua Liu, Aijie Zhang, You Zhou   +7 more
wiley   +1 more source

A post-transplant optimized transplant-specific risk score in myelodysplastic syndromes

Haematologica, 2019
Mahasweta Gooptu, John Koreth
doaj   +1 more source

Bispecific Antibodies in Hematologic Malignancies in the Outpatient and Community Settings. [PDF]

Adv Hematol
Gonugunta AS, Haider A, Mohlere V, Aljurf M, Hashmi S, Abid MB.   +5 more
europepmc   +1 more source

Mitochondrial Carrier SLC25A13 Drives Ferroptosis Resistance and Immune Evasion via a STAT3–IFI6 Circuit in Breast Cancer

Advanced Science, EarlyView.
SLC25A13 is identified as an immunometabolic driver of triple‐negative breast cancer that sustains ferroptosis resistance and immune evasion through a STAT3–IFI6 circuit. Pharmacologic degradation of SLC25A13 restores ferroptosis sensitivity and enhances anti‐PD‐1 efficacy, highlighting a strategy to convert immune‐cold tumors into immunotherapy ...
Yingze Zhu, Yuhan Tang, Yingcui Chen, Zhuoqi Zhang, Yige Lu, Xinyue Wang, Qiyuan Shi, Wenhui Zhao, Hui Pang   +8 more
wiley   +1 more source

Consensus radiation therapy organ at risk constraints for NCTN trials in hematologic malignancies. [PDF]

J Natl Cancer Inst
Sim AJ, Hoppe BS, Ballas LK, Milgrom SA, Terezakis SA, Ha CS, Figura NB, Parikh RR, Grecula JC, Plastaras JP, Lo AC, Ryckman J, Flampouri S, Pinnix CC, Kelsey CR.   +14 more
europepmc   +1 more source

Heat Shock Protein 90: From Molecular Chaperone Function to Therapeutic Targeting in Malignancies

Advanced Science, EarlyView.
In this review, an integrated conceptual framework linking HSP90's molecular chaperone functions to its pathological roles in cancer is proposed. HSP90 serves as a central node that integrates oncogenic signaling, buffers proteotoxic stress, maintains cancer stem cell plasticity, and shapes tumor‐immune interactions, all of which converge to drive ...
Beibei Zhang, Xinxin Zou, Jiansong Zhou, Qinmiao Sun, Dahua Chen   +4 more
wiley   +1 more source